Can you take Thymosin Beta-4 Fragment (TB4-Frag 17-23) and Thymosin Beta-4 together?

There is no specific, well-documented interaction rule for combining Thymosin Beta-4 Fragment (TB4-Frag 17-23) and Thymosin Beta-4 in the aggregated research reviewed. Combining peptides should only be considered under professional supervision. This is not medical advice.

Which is better researched, Thymosin Beta-4 Fragment (TB4-Frag 17-23) or Thymosin Beta-4?

Thymosin Beta-4 Fragment (TB4-Frag 17-23) is currently research-stage and Thymosin Beta-4 is investigational (in trials). "Better researched" depends on your research goal — review each profile's cited sources.

Healing & Recovery · Comparison

Thymosin Beta-4 Fragment (TB4-Frag 17-23) vs Thymosin Beta-4

Q: What is the difference between Thymosin Beta-4 Fragment (TB4-Frag 17-23) and Thymosin Beta-4?

Thymosin Beta-4 Fragment (TB4-Frag 17-23): The heptapeptide fragment (amino acids 17–23) of full thymosin beta-4, sequence Ac-LKKTETQ. This sequence is the active actin-binding domain responsible for TB-500's tissue repair properties. Shorter molecular weight than TB-500 enables more targeted delivery while retaining identical mechanism of action on G-actin regulation and tissue repair signaling. Thymosin Beta-4: Thymosin Beta-4 (TB4) is the full-length 43-amino acid peptide produced naturally in high concentrations in platelets, wound fluid, and regenerating tissue. It is the parent molecule from which the popular TB-500 research peptide (the 17-23 fragment Ac-LKKTETQ) is derived. TB4 promotes actin polymerization, accelerates wound healing, reduces inflammation, and supports cardiac and neurological repair in preclinical models. Both are in the Healing & Recovery category but differ in mechanism, dosing, and research evidence — see the full comparison.

A neutral, side-by-side comparison of two healing & recovery peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.

Thymosin Beta-4 Fragment (TB4-Frag 17-23)

Research-stage

The heptapeptide fragment (amino acids 17–23) of full thymosin beta-4, sequence Ac-LKKTETQ. This sequence is the active actin-binding domain responsible for TB-500's tissue repair properties. Shorter molecular weight than TB-500 enables more targeted delivery while retaining identical mechanism of action on G-actin regulation and tissue repair signaling.

Full profile

Thymosin Beta-4

Investigational (in trials)

Thymosin Beta-4 (TB4) is the full-length 43-amino acid peptide produced naturally in high concentrations in platelets, wound fluid, and regenerating tissue. It is the parent molecule from which the popular TB-500 research peptide (the 17-23 fragment Ac-LKKTETQ) is derived. TB4 promotes actin polymerization, accelerates wound healing, reduces inflammation, and supports cardiac and neurological repair in preclinical models.

Full profile

	Thymosin Beta-4 Fragment (TB4-Frag 17-23)	Thymosin Beta-4
Category	Healing & Recovery	Healing & Recovery
Also known as	TB4 fragment 17-23, TB-500 active peptide, LKKTETQ, thymosin beta-4 fragment, Ac-LKKTETQ	TB4, Tβ4, Tβ4 full-length
Evidence	Research-stage	Investigational (in trials)
Dosing range	250mcg–1mg mcg–mg, 2–3x weekly	500mcg–2000mcg mcg, 2–3x weekly
Administration	Subcutaneous injection, Intramuscular injection	Subcutaneous injection, Intramuscular injection, Intravenous (clinical studies only)
Key side effects	Injection site irritation, Mild fatigue (transient), Potential headache, Generally well-tolerated in research applications	Injection site discomfort (mild), Transient fatigue post-injection, Headache (uncommon), Theoretically may accelerate growth of pre-existing malignant tumors (promotes angiogenesis and cell migration — use with caution)
Cited sources	2 references	3 references

Key differences

Evidence level differs: Thymosin Beta-4 Fragment (TB4-Frag 17-23) is research-stage, while Thymosin Beta-4 is investigational (in trials).
Administration: Thymosin Beta-4 Fragment (TB4-Frag 17-23) — Subcutaneous injection, Intramuscular injection; Thymosin Beta-4 — Subcutaneous injection, Intramuscular injection, Intravenous (clinical studies only).
Dosing units differ: Thymosin Beta-4 Fragment (TB4-Frag 17-23) is dosed in mcg–mg, Thymosin Beta-4 in mcg — they operate at different scales.
Research depth: this profile cites 2 sources for Thymosin Beta-4 Fragment (TB4-Frag 17-23) vs 3 for Thymosin Beta-4.

How each works

Thymosin Beta-4 Fragment (TB4-Frag 17-23)

The LKKTETQ sequence was identified in 1994 as the minimum active fragment of thymosin beta-4 responsible for its actin-sequestering and tissue repair activity. This heptapeptide competes with actin monomer binding proteins, promoting cell migration, angiogenesis, and wound healing. Studies confirm it recapitulates the key bioactivity of full TB4 in cell migration and collagen deposition assays.

Thymosin Beta-4

TB4's primary mechanism involves sequestering G-actin monomers (via its LKKTET actin-binding domain) to regulate actin cytoskeleton dynamics — critical for cell migration, wound closure, and tissue remodeling. Clinical trials have evaluated TB4 for corneal wound healing (Phase 2), pressure ulcers, and cardiac repair after MI. The FACT trial investigated TB4 in patients with ischemic heart failure, showing trends toward improved cardiac function. Anti-inflammatory effects are mediated partly through NF-κB pathway downregulation.

Read the full Thymosin Beta-4 Fragment (TB4-Frag 17-23) profile Read the full Thymosin Beta-4 profile

This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.